[生物制药在类风湿关节炎治疗中的应用]
[Biopharmaceuticals in the treatment of rheumatoid arthritis].
作者信息
Baslund Bo, Bendtzen Klaus
机构信息
Rigshospitalet, Reumatologisk klinik TA, København Ø.
出版信息
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10.
PMID:18572481
Abstract
The current status on the use of biopharmaceuticals in the treatment of rheumatoid arthritis is reviewed. Blocking of TNF-alpha, co-stimulation of CD28+ T-cells and depletion of CD20+ B-cells are all effective ways to diminish inflammation and joint damage. However, not all patients react to these treatments, and the development of biomarkers to predict which patients will benefit from these drugs is therefore warranted.
摘要
本文综述了生物制药在类风湿性关节炎治疗中的应用现状。阻断肿瘤坏死因子-α、共刺激CD28 + T细胞以及清除CD20 + B细胞都是减轻炎症和关节损伤的有效方法。然而，并非所有患者对这些治疗都有反应，因此有必要开发生物标志物来预测哪些患者将从这些药物中获益。
相似文献
1
[Biopharmaceuticals in the treatment of rheumatoid arthritis].
Ugeskr Laeger. 2008 Jun 9;170(24):2108-10.
2
3
Emerging biologic drugs for the treatment of rheumatoid arthritis.
Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016.
4
[TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med. 2002 May 16;144(20):65.
5
Drugs for rheumatoid arthritis.
Treat Guidel Med Lett. 2012 May;10(117):37-44; quiz 2 p following 44.
6
Autoimmune diseases. The B cell slayer.
Science. 2007 Nov 23;318(5854):1232-3. doi: 10.1126/science.318.5854.1232.
7
Management of rheumatoid arthritis.
Natl Med J India. 2004 May-Jun;17(3):143-51.
8
Emerging therapeutics for rheumatoid arthritis.
Bull NYU Hosp Jt Dis. 2008;66(3):210-5.
9
Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Handb Exp Pharmacol. 2008(181):163-81. doi: 10.1007/978-3-540-73259-4_8.
10
[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Clin Calcium. 2007 Apr;17(4):569-76.
Zotero 插件